Table 2 Scheduled measurements of primary and secondary outcomes

 KOOS pain subscale

x

x

x

x

x

x

 Adverse events

x

 Hospitalization

x

x

x

x

x

 Co-interventions (iMCQ)

x

x

x

x

x

 Medication use for knee OA

x

x

x

x

x

x

 Re-injection with glucocorticoid

x

x

x

 KOOS stiffness

x

x

x

x

x

x

 KOOS function in daily living

x

x

x

x

x

x

 KOOS sports and recreation

x

x

x

x

x

x

 KOOS QoL

x

x

x

x

x

x

 ICOAP

x

x

x

x

x

x

 OMERACT OARSI responder criteria

x

x

x

x

x

 Knee pain over past week (NRS)

x

x

x

x

x

x

x

 Perceived recovery (Likert scale)

x

x

x

x

x

 Knee complaint characteristics

x

x

x

x

x

x

 Health related QoL

x

 Radiograph of study knee

x

 Check of ACR criteria

x

 Painfulness of injection (NRS)

x

 Demographic information

x

 Co-morbidity

x

 Physical activity over the past week (IPAQ short)

x

 Neuropathic pain (Modified painDETECT Questionnaire)

x

 Patients’ preferred injection site

x

 Patients’ expected treatment response

x